Vertex Ventures HC
San Francisco, California, United StatesFounded 2014
Vertex Ventures HC is a global healthcare investment firm that focuses on backing life sciences and medical technology companies across biopharmaceuticals, medical devices, and digital health. Their strategy involves investing in early-stage to commercial-stage companies with disruptive technologies and breakthrough research, aiming to drive innovation and improve patient outcomes in areas of significant unmet need.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (67% of deals). Average disclosed round size is $116.0M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
$550M
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 SpyGlass Pharma | Series D | $75M | Jun 2025 |
| TTORL BioTherapeutics, LLC | Series B | $158M | Apr 2024 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
Top Co-Investors
RA Capital Management2 shared
Samsara BioCapital2 shared
Surveyor Capital1 shared
Cowen Healthcare Investments1 shared
Deep Track Capital1 shared
Logos Capital1 shared
Pivotal bioVenture Partners1 shared
Soleus Capital1 shared
Atlas Venture1 shared
Amgen1 shared
Bristol Myers Squibb1 shared
Vertex Pharmaceuticals1 shared
Sands Capital1 shared
Gilde Healthcare1 shared
Vensana Capital1 shared
Moore Strategic Ventures1 shared
Last updated: 8 March 2026